Massive MGUS screening aims to unlock early myeloma clues
NCT ID NCT06472830
First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times
Summary
This study screens 1000 adults aged 40 and older for MGUS, a condition with an abnormal blood protein that can sometimes lead to multiple myeloma. Researchers want to learn about genetic and immune factors behind MGUS, especially in diverse populations. The goal is to improve early detection and future care for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 1,000 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2024
- Expected to finish
-
May 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adults attending primary care clinics at Mayo Clinic and Mayo Clinic Health Systems, or health fairs and events
- Ages
-
40 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults ≥ 40 years * Willing and able to review, understand, and provide consent before starting any study-specific procedures * Ability to complete questionnaire(s) by themselves or with assistance Exclusion Criteria: * Pregnant women
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Monoclonal gammopathy of undetermined significance are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Gene clues may unlock new treatments for bone marrow cancer
- New blood test screening targets hidden cancer in black communities
- Gut bacteria drug shows promise against blood disorder
- Turmeric and black pepper extract shows promise in slowing early cancers
- 1,000 volunteers help scientists unlock the mystery of myeloma progression
- New italian network aims to catch rare blood disease earlier